Effectiveness and Safety of Zilucoplan Treatment for French Patients with Myasthenia Gravis Over 3 Months

Centre Hospitalier Universitaire de Nice

Status: Not yet enrolling

Conditions: Myasthenia Gravis

Treatments: Drug: Zilbrysq

Study type: Observational

Funder types: Other

Identifiers

NCT06815133

25Neuro01

Details and patient eligibility

About

This study called "Multicenter Retrospective Study on the Short- and Medium-Term Efficacy and Tolerance of Zilucoplan Therapy in a Cohort of French Patients with Anti-AChR Myasthenia Gravis", is investigating the effects of a new treatment called Zilucoplan (generic name: ZILBRYSQ) on patients in France with a condition known as myasthenia gravis. Myasthenia gravis is an autoimmune disease that causes muscle weakness that worsens throughout the day with activity and impacts the ability to work and perform daily activities. The study aims to see if Zilucoplan can improve muscle strength and quality of life over three months, while also assessing its tolerance and safety by monitoring side effects. Researchers hope this treatment will offer significant benefits for people with this challenging condition.

Enrollment: 55 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of myasthenia gravis with anti-AChR antibodies in patients treated with Zilucoplan

Exclusion criteria

• None

Trial design

55 participants in 1 patient group

Patients with Anti-AChR Myasthenia Gravis treated with Zilucoplan

Treatment:

Drug: Zilbrysq